AR036258A1 - Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto. - Google Patents
Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto.Info
- Publication number
- AR036258A1 AR036258A1 ARP020103032A ARP020103032A AR036258A1 AR 036258 A1 AR036258 A1 AR 036258A1 AR P020103032 A ARP020103032 A AR P020103032A AR P020103032 A ARP020103032 A AR P020103032A AR 036258 A1 AR036258 A1 AR 036258A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- lower alkyl
- optionally substituted
- alkyl
- branched
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- -1 quinazolin-5-one compound Chemical class 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto 1-alquil o 1-cicloalquil-triazolo [4-3-a] quinazolin-5-onas de la fórmula (1) en donde R1 se selecciona de: hidroxilo, halógeno, nitro, mercapto, ciano o carboxilo, alquilo inferior o alcoxi inferior, estos grupos son optativamente sustituidos con 1, 2 o 3 átomos de halógeno, NR4R5 en donde R4 y R5 son iguales o diferentes y se seleccionan de; H, alquilo inferior, optativamente sustituido con 1, 2 o 3 grupos seleccionados de halógeno, hidroxilo, ciano y alcoxi inferior, - C(=O)R6 en donde R6 se selecciona de: alquilo inferior optativamente sustituido con OR7 o SR7, o -X1-cicloalquilo optativamente sustituido con OR7, SR7, NR7R8 o con un alquilo de C1-4 lineal o ramificado, en donde R7 y R8 son iguales o diferentes y se seleccionan de hidrógeno o alquilo inferior y X1 es un enlace simple o alquileno de C1-4 lineal o ramificado; R2 se selecciona de: alquilo inferior optativamente sustituido con OR9 SR9 o X2-cicloalquilo optativamente sustituido con OR9, SR9, NR9R10 o con alquilo de C1-4 lineal o ramificado. En donde R9 y R10 son iguales o diferentes y se seleccionan de hidrógeno o alquilo inferior y X2 es un enlace simple o un alquileno de C1-4 lineal o ramificado; -R3 se selecciona de: fórmula (2) en donde: n es un número entero de 1 a 4, Ar es un anillo aromático que comprende 5 o 6 átomos que incluyen de 0 a 3 heteroátomos elegidos de O, S y N, Y1, Y2 e Y 3 que pueden ser idénticos o diferentes, representan: hidrógeno, hidroxilo, mercapto, nitro, halógeno, C(=O)R11, C(=O)R11, C(=O)NR12R13, NR12R13 o -(CH2)s CN en donde s es un número entero de 0 a 2, R11, R12 y R13 se seleccionan de hidrógeno o alquilo inferior, o alquilo inferior o alcoxi inferior, cada uno optativamente sustituido con 1, 2 o 3 átomos de halógeno, o -S(O)mR14 en donde m es 0, 1 o 2 y R14 es un alquilo inferior; y optativamente las formas racémicas y formas isoméricas de este, así como las sales farmacéuticamente aceptables de este, para su uso como medicamento. Una composición farmacéutica que lo comprende y uso de un compuesto de la fórmula (1) para la preparación de un medicamento para la prevención o el tratamiento de enfermedades para las cuales la terapia con un inhibidor de PDE4 es relevante, como cáncer, SIDA y fibrosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01402166A EP1285922A1 (en) | 2001-08-13 | 2001-08-13 | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036258A1 true AR036258A1 (es) | 2004-08-25 |
Family
ID=8182851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020103032A AR036258A1 (es) | 2001-08-13 | 2002-08-12 | Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6747035B2 (es) |
| EP (2) | EP1285922A1 (es) |
| JP (1) | JP2005502662A (es) |
| AR (1) | AR036258A1 (es) |
| BR (1) | BR0211863A (es) |
| CA (1) | CA2453647A1 (es) |
| DO (1) | DOP2002000447A (es) |
| HN (1) | HN2002000208A (es) |
| PA (1) | PA8552501A1 (es) |
| PE (1) | PE20030344A1 (es) |
| SV (1) | SV2003001173A (es) |
| WO (1) | WO2003016314A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040242566A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| CN1867560A (zh) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4－嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
| EP1699777B1 (en) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102127053A (zh) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| EP2805953B1 (en) | 2004-12-21 | 2016-03-09 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| ME02005B (me) | 2005-09-14 | 2012-08-31 | Takeda Pharmaceuticals Co | Inhibitori dipeptidil peptidaze za lečenje dijabetesa |
| CA2622642C (en) | 2005-09-16 | 2013-12-31 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2026813A2 (en) | 2006-05-09 | 2009-02-25 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
| US8324383B2 (en) * | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| CA2663279C (en) * | 2006-09-13 | 2016-05-17 | Takeda Pharmaceutical Company Limited | Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US8093236B2 (en) * | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| US20100144140A1 (en) * | 2008-12-10 | 2010-06-10 | Novellus Systems, Inc. | Methods for depositing tungsten films having low resistivity for gapfill applications |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| MD20150071A2 (ro) | 2013-02-19 | 2016-02-29 | Pfizer Inc. | Compuşi azabenzimidazolici ca inhibitori ai PDE4 izoenzimelor pentru tratamentul tulburărilor SNC şi altor afecţiuni |
| JP6713982B2 (ja) | 2014-07-24 | 2020-06-24 | ファイザー・インク | ピラゾロピリミジン化合物 |
| JP6506833B2 (ja) | 2014-08-06 | 2019-04-24 | ファイザー・インク | イミダゾピリダジン化合物 |
| DK3766885T3 (da) | 2015-06-17 | 2022-08-01 | Pfizer | Tricykliske forbindelser og deres anvendelse som phoshodiesteraseinhibitorer |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
| EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD158549A1 (de) * | 1981-05-13 | 1983-01-19 | Karl Kottke | Verfahren zur herstellung von 1,4,7,9-verschieden substituierten 4,5-dihydro-s-triazolo(4,3-a)chinazolin-5-onen |
| IL66835A (en) * | 1981-09-24 | 1988-05-31 | Roussel Uclaf | 1,4-disubstituted(1,2,4)triazolo(4,3-alpha)quinazolin-5(4h)-one derivatives and their salts,their preparation and pharmaceutical compositions containing them |
| CA2319435A1 (en) * | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Triazolo derivatives and chemokine inhibitors containing the same as effective component |
| FR2792938B1 (fr) * | 1999-04-28 | 2001-07-06 | Warner Lambert Co | NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV |
-
2001
- 2001-08-13 EP EP01402166A patent/EP1285922A1/en not_active Withdrawn
-
2002
- 2002-06-26 CA CA002453647A patent/CA2453647A1/en not_active Abandoned
- 2002-06-26 WO PCT/EP2002/007061 patent/WO2003016314A1/en not_active Application Discontinuation
- 2002-06-26 BR BR0211863-7A patent/BR0211863A/pt not_active IP Right Cessation
- 2002-06-26 EP EP02747440A patent/EP1419159A1/en not_active Withdrawn
- 2002-06-26 JP JP2003521236A patent/JP2005502662A/ja not_active Withdrawn
- 2002-07-17 SV SV2002001173A patent/SV2003001173A/es not_active Application Discontinuation
- 2002-08-02 US US10/211,134 patent/US6747035B2/en not_active Expired - Fee Related
- 2002-08-09 PE PE2002000722A patent/PE20030344A1/es not_active Application Discontinuation
- 2002-08-09 PA PA20028552501A patent/PA8552501A1/es unknown
- 2002-08-09 HN HN2002000208A patent/HN2002000208A/es unknown
- 2002-08-12 DO DO2002000447A patent/DOP2002000447A/es unknown
- 2002-08-12 AR ARP020103032A patent/AR036258A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20030069260A1 (en) | 2003-04-10 |
| CA2453647A1 (en) | 2003-02-27 |
| SV2003001173A (es) | 2003-04-03 |
| EP1285922A1 (en) | 2003-02-26 |
| JP2005502662A (ja) | 2005-01-27 |
| PE20030344A1 (es) | 2003-04-10 |
| WO2003016314A1 (en) | 2003-02-27 |
| BR0211863A (pt) | 2004-09-21 |
| PA8552501A1 (es) | 2003-06-30 |
| DOP2002000447A (es) | 2003-02-15 |
| HN2002000208A (es) | 2003-02-27 |
| US6747035B2 (en) | 2004-06-08 |
| EP1419159A1 (en) | 2004-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036258A1 (es) | Compuesto 1-alquil o 1-cicloalquiltriazolo [4,3-a] quinazolin-5-ona, composicion farmaceutica que lo comprende, uso de dicho compuesto para preparar un medicamento y proceso para la preparacion de dicho compuesto. | |
| PL402388A1 (pl) | Pochodna pirymidyny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca | |
| BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
| BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
| BR0210507A (pt) | Azaindóis | |
| AR035936A1 (es) | Inhibidores de metaloproteinasas de matriz piridinica, derivados de piridina, composiciones farmaceuticas y usos de los mismos en la fabricacion de medicamentos | |
| PE20040999A1 (es) | Nuevas pirazolopirimidinas como inhibidores de cinasas dependientes de ciclinas | |
| AR035505A1 (es) | Derivados de naftaleno como compuestos de enlace de receptor canabinoide, procesos para su produccion, su uso como productos farmaceuticos para el tratamiento o la prevencion de una enfermedad o condicion en donde tenga un papel o este implicada la activacion del receptor canabinoide y composiciones | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| PT1263725E (pt) | Novos compostos | |
| AR033367A1 (es) | Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos | |
| UY27368A1 (es) | Nuevos compuestos | |
| EA200300929A1 (ru) | Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv | |
| SE0101387D0 (sv) | Novel compounds | |
| DK1299382T3 (da) | Præparat og antiviral virkning af substituerede indoloxoeddikesyrepiperazinderivater | |
| UY27592A1 (es) | Nuevo uso | |
| HK1060067A1 (en) | Compositions for antitumour treatment containing ecteinascidin 743 | |
| MXPA03010761A (es) | Combinaciones farmaceuticas. | |
| DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| SE0102440D0 (sv) | New compound | |
| GEP20043227B (en) | 5HT1 Antagonists for Antidepressant Therapy | |
| GB0310726D0 (en) | Therapeutic agents | |
| PT902684E (pt) | Derivados hexa-hidro-pirido(4,3-b)indolo utilizados como farmacos antipsicoticos | |
| BRPI0211025B8 (pt) | um novo composto para o tratamento da impotência | |
| DE602005017629D1 (de) | Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |